Chapter 60

## Abstract

Abstract

1. Neuroblastoma, a tumor of the postganglionic sympathetic nervous system, is the most common extracranial solid tumor of childhood.

2. No environmental exposures or agents have been associated with an increased risk of neuroblastoma. However, a subset has a genetic predisposition that follows an autosomal dominant pattern of inheritance.

3. Primary tumors generally arise in the adrenal medulla (50 percent) or elsewhere in the abdomen or pelvis (30 percent). Only 20 percent arise in the chest.

4. Metastases usually are found in the regional lymph nodes, bone, bone marrow, skin, or liver. Paraneoplastic syndromes characteristic of neuroblastomas are seen in a small percentage of patients.

5. Tissue biopsy or characterization of cells in the bone marrow diagnoses neuroblastomas. Catecholamine metabolites are elevated in the urine in over 90 percent of cases.

6. There is an international neuroblastoma staging system for categorizing the extent and resectability of the primary tumor and the presence or absence of metastases.

7. A number of prognostic variables have been identified that allow better prediction of clinical behavior: MYCN amplification, allelic loss of 1p36, gain of 17q, expression of TrkA, tumor cell ploidy, and tumor pathology.

8. Histologically, neuroblastic tumors can be immature (neuroblastoma), partially mature (ganglioneuroblastoma), or completely mature (ganglioneuroma). However, other features, such as the presence or absence of Schwannian stroma, mitoses, or karyorrhectic cells, may have more prognostic importance.

9. Localized, resectable tumors can be cured by surgery alone. Unresectable tumors or metastatic disease in infants require mild to moderately intensive chemotherapy. Metastatic disease in older patients, and regional tumors with unfavorable biological features in any age, require intensive chemotherapy, frequently with bone marrow or stem cell rescue.

10. Screening of infants for neuroblastoma by measuring urinary catecholamine metabolites has resulted in a doubling of the apparent incidence rate in infants with no decrease in advanced disease in older children.

11. Future therapeutic approaches may be aimed at the induction of differentiation or programmed cell death through retinoid or neurotrophin receptor pathways. Alternate approaches may focus on the product of the MYCN gene, the 1p36 suppressor gene, other specific genetic changes, or antiangiogenesis.

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

## Subscription Options

### OMMBID Full Site: One-Year Subscription

Connect to the full suite of OMMBID content including new and revised chapters that reflect the latest research, image galleries, clinical phenotypes, and more.

$295 USD ### Pay Per View: Timed Access to all of OMMBID 24 Hour Subscription$34.95

48 Hour Subscription \$54.95

### Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.